We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA Advisers Recommend Approval for Exubera
EMEA Advisers Recommend Approval for Exubera
October 14, 2005
Pfizer and sanofi-aventis received more positive news last week on their highly anticipated inhaled insulin drug Exubera when a European Medicines Agency (EMEA) advisory committee recommended approval of the product for Type 1 and 2 diabetes.